Temperature-sensitive mutant vaccines protect rats against Mycoplasma pulmonis infection. The role of the humoral or cellular immune response in resistance to mycoplasma infection was investigated by adoptivetransfer experiments. Spleen cells from Lewis rats vaccinated but not challenged with wild-type organisms (vaccinated) and spleen cells from rats vaccinated (or not) and challenged were effective in preventing syngeneic recipients from developing respiratory disease. There was also a significant reduction in the incidence and number of challenging organisms in the respiratory system. In contrast, sera from the same donors had no detectable effect on the number of mycoplasmas recovered or on lesion development in the respiratory tract. We conclude that cellular immunity rather than humoral immunity generated in vaccinated rats confers protection against subsequent infection.
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Mycoplasma pulmonis is one of the most important diseases in both conventionally maintained and specific-pathogen-free rodent colonies. Studies of the immune mechanisms in experimentally induced murine respiratory mycoplasmosis (MRM) should provide useful information for the control of MRM infections. To develop suitable vaccines, it is necessary to understand the mechanisms involved in resistance to reinfection. The interaction of circulating antibodies, local secretory antibodies, natural killer (NK) cells, and cell-mediated immunity in mycoplasma infections is not known.
When an animal is exposed to mycoplasmas, the organisms often persist in the respiratory tract for prolonged periods. For example, carriage of M. pneumoniae in the upper respiratory tracts of humans may persist for several weeks (13) , while in mice inoculated intranasally (i.n.) with M. pulmonis, both the pneumonic lesions and the mycoplasmas persist for several months (21) . This suggests that the host's immune response is inefficient. However, persistently infected animals are resistant to subsequent i.n. challenge with the same organism. Thus, mice inoculated i.n. with small numbers of M. pulmonis organisms do not develop lung lesions, although mycoplasmas can be isolated from their lungs for at least several weeks postinoculation. Following i.n. challenge with a large dose of M. pulmonis, which produces severe pneumonia in control animals, mice previously inoculated with small numbers of mycoplasmas develop much less severe pneumonia and fewer organisms are isolated from their lungs than from those of controls (26 tive in the two species differ. In infected rats, bronchial tract-associated lymphoid tissue hyperplasia is predominant, whereas in mice a plasma cell response is predominant (22) . In contrast to the case in mice (25) (26) (27) , preexisting antibodies are not protective in rats. Levels of passively acquired maternal antibody are quite high in offspring, and antibody production in pups begins within the first 6 weeks of life. However, this antibody does not protect against colonization and subsequent development of disease (6) . Furthermore, immune spleen cells, but not immune serum, can confer protection in normal syngeneic naive rats (2) .
We have developed a vaccination protocol for rats by using a temperature-sensitive mutant (TSM) of M. pulmonis (15) . Therefore, we felt that it was important to understand more fully the importance of serum antibody and cellular immunity in resistance to MRM, especially after vaccination. We compared the abilities of spleen cells and serum from rats vaccinated with the TSM to immunize syngeneic Lewis rats passively.
MATERIALS AND METHODS
Experimental animals. Specific-pathogen-free, 5 [19] ). The cell suspensions were also cultured in Chalquest agar medium to test for M. pulmonis. The ratio of donor spleen cells equivalent to recipient animals was 2:1. Recipient syngeneic rats were infused intravenously with 6 x 108 cells or 3 to 4 ml of serum and challenged 2 h later with 107 CFU of M. pulmonis inoculated i.n. Rats were humanely killed 28 days after i.n. challenge. Nasopharyngeal ducts, tympanic bullae, and tracheolung lavages were collected and titrated for mycoplasma, and the whole respiratory systems were collected and examined for histopathological changes.
Mycoplasma isolation, titration, and identification. The procedures for mycoplasma isolation, titration, and identification were modified as described previously (20 M. pulmonis infection in passively immunized rats. Since the rats vaccinated with TSMs were protected against wildtype M. pulmonis infection, it was important to determine the abilities of cells and sera obtained from these rats to protect syngeneic recipients. Therefore, pooled spleen cells or sera obtained from group 1 and 2 rats were mixed together and referred to as immune cells or sera to be examined from rats infected with wild-type M. pulmonis. The antibody titers for pooled immune sera in the ELISA was 2 x 104 for immunoglobulin G (IgG) and 5 x 102 for IgM. These were the peak titers obtained. Spleen cells and sera collected from group 3 control rats were tested in parallel. Control sera contained no IgG or IgM (titer, <101). Pooled sera and spleen cells from group 4 (vaccinated, not challenged) were considered vaccinated sera or cells. The peak titers of IgG and IgM in this group were 103 and 102, respectively, and were also examined. No mycoplasmas were isolated from immune, vaccinated, or normal sera. Immune and vaccinated spleen cells had stimulation indices of 30 and 25, respectively, against sonicated M. pulmonis cell membranes, which were significantly higher (P < 0.05) than that of normal control (group 3) cells (stimulation index, 3). These results suggested that immune and vaccinated spleen cells contained memory T cells. A small number of M. pulmonis organisms were isolated from pooled immune (group 1 and 2) cell suspensions but not from normal or vaccinated (group 3 or 4) cell suspensions.
Effects of passively transferred cells. (i) Lung lesions. Twenty-eight days after i.n. challenge, the pneumonia lesion indices were 0.21, 0.24, and 0.83 in rats that received immune, vaccinated, and control cells, respectively ( Table  1 ). The differences between the two experimental groups and the controls were highly significant (P < 0.01). The prevalences of lung lesions in rats which had received immune, vaccinated, and control spleen cells were 22, 27, and 100%, respectively. These differences were also significant (P < 0.01). These data indicate that rats which received immune or vaccinated spleen cell suspensions could inhibit the frequency and severity of lung lesions induced by mycoplasma infection.
(ii) Isolation of M. pulmonis. Another criterion used to evaluate protection is whether passively transferred cells or sera can prevent colonization by the wild-type challenge organism and reduce the frequency or number of wild-type organisms in the respiratory tract postchallenge. The results of this study are presented in Table 2 . Samples were taken from nasopharyngeal ducts, tympanic bullae, and tracheolung lavages and cultured on Chalquest agar medium. Rats that received immune or vaccinated cells had 106-fold fewer organisms in each area than did rats that received normal cells (P < 0.001). The incidences of recovery of challenge organisms was 27, 32, and 100% for rats which received immune, vaccinated, and normal spleen cells, respectively.
Effects of passively transferred serum. Notable gross lesions, such as atelectasis, consolidation, and bronchiectasis, were observed in rats which received immune, vaccinated, or normal serum and were challenged with M. pulmonis. Microscopically, all of the rats in these three groups developed severe pneumonia. The mean lesion index scores were 0.80, 0.75, and 0.85 for the immune, vaccinated, and normal serum groups, respectively ( Table 1 ). The differences were not significant.
Immune or vaccinated serum (or normal serum) also failed to prevent recipient animals from colonization by M. pulmonis UAB 6510 28 days after i.n. challenge ( Table 2 ). All of the rats from the three groups had large numbers of M. pulmonis organisms at the three sites tested, and there were no significant differences in numbers of M. pulmonis organisms detected.
DISCUSSION
Since rats vaccinated with TSMs were protected against wild-type M. pulmonis, it was important to determine the (Tables 1 and 2 ). This protective effect included significant reduction in the prevalence and number of organisms and the severity of lung lesions. Immune sera taken from the very same donor rats showed no significant protection against acute infection, although the IgG and IgM anti-M. pulmonis titers of the sera used were quite high. We chose M. pulmonis UAB 6510 to challenge the animals because this strain was isolated originally from a rat lung and causes severe lung lesions in infected rats (3, 7) . Lewis rats were chosen because they are genetically susceptible to this disease (7) It has long been noted that the histopathological changes of respiratory disease caused by M. pulmonis in rats and mice are different (22) . This suggests that the immune mechanisms operative in the two species also differ. In infected rats, lymphocytic hyperplasia is predominant, whereas in mice, a plasmacytic response is predominant. Preexisting antibody or passively transferred antibody can protect mice (5, (25) (26) (27) but not rats (6) . In contrast, immune cells protect against experimental infection in genetically resistant F344 strain rats (2) . It has been reported that there are differences in the responses of rat strains F344 and LEW (7, 10, 11) and various mouse strains (9, 24) to infection with M. pulmonis. The differences in the relative importance of cellular and antibody-mediated mechanisms of resistance to M. pulmonis may have been related to strain (resistant versus susceptible) rather than species differences (14) . However, both resistant F344 (2) and susceptible Lewis (this report) rats transfer passive immunity with cells but not with sera. We therefore conclude that rats and mice differ in their mechanisms of immune protection.
T cells were no doubt present in our immune and vaccinated spleen cell suspensions and may have played a critical role in protection. A definitive confirmatory test would be to compare CD4 and/or CD8 T-cell-depleted spleen cell suspensions with control immune or vaccinated spleen cell suspensions in cell transfer studies.
Numerous cells infiltrate lungs of rats and mice following M. pulmonis infection (4, 8, 11) . A significant number of cells (about 50% in tissue sections) were morphologically indistinguishable from lymphocytes, which failed to stain with either T-or B-cell reagents, and were called null cells. One potential cell type is the NK cell. NK cells play a significant role in resistance to M. pulmonis infection (17) . M. pulmonis infection augments NK cell activity in spleens and lungs of infected animals (17, 18) . We have observed that NK cells exposed to viable M. pulmonis release gamma interferon, which either directly kills the mycoplasmas or indirectly activates macrophages to engulf and digest M. pulmonis (16, 17 
